Health Care • Medical Specialities
$68.62 ▲ +1.57
(+2.34%)
MKT CAP: $33.97B • VOL: 5.63M
52W L $32 52W H $73
CNC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $174.58B | $145.50B | $140.09B |
| YoY Revenue Growth % | +20.0% | +3.9% | — |
| Gross Profit | $14.21B | $17.07B | $61.64B |
| Gross Margin % | 8.1% | 11.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.62B | $3.17B | $2.93B |
| Operating Margin % | -4.4% | 2.2% | 2.1% |
| Net Income (GAAP) | -$6.67B | $3.31B | $2.70B |
| EBITDA (Normalized) | -$7.01B | $3.69B | $7.97B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $5.09B | $154.0M | $8.05B |
| Capital Expenditures (CapEx) | $767.0M | $644.0M | $6.30B |
| Free Cash Flow (FCF) | $4.32B | -$490.0M | $1.75B |
| FCF Margin % | 2.5% | -0.3% | 1.2% |
| Return on Invested Capital (ROIC %) | -31.0% | 8.2% | 2.3% |
| Cash & Short-Term Equivalents | $17.89B | $14.06B | $18.49B |
| Total Debt (Short + Long Term) | $17.35B | $18.42B | $39.34B |
| Total Stockholders' Equity | $19.95B | $26.41B | $80.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNC.